AFIB - Acutus Medical, Inc. Stock Price, Fair Value and News

0.17USD0.00 (0.00%)Delayed as of 22 Apr 2024, 12:54 pm ET

Market Summary

USD0.170.00

Delayedas of 22 Apr 2024, 12:54 pm

0.00%

AFIB Stock Price

View Fullscreen

AFIB RSI Chart

AFIB Valuation

Market Cap

5.1M

Price/Earnings (Trailing)

-0.06

Price/Sales (Trailing)

0.71

EV/EBITDA

3.52

Price/Free Cashflow

-0.08

AFIB Price/Sales (Trailing)

AFIB Profitability

EBT Margin

-165.52%

Return on Equity

-257.56%

Return on Assets

-151.34%

Free Cashflow Yield

-1.3K%

AFIB Fundamentals

AFIB Revenue

Revenue (TTM)

7.2M

Rev. Growth (Yr)

43.74%

Rev. Growth (Qtr)

-0.96%

AFIB Earnings

Earnings (TTM)

-81.7M

Earnings Growth (Yr)

-323.49%

Earnings Growth (Qtr)

-155.08%

Breaking Down AFIB Revenue

52 Week Range

0.171.09

(Low)(High)

Last 30 days

-10.5%

Last 90 days

-5.6%

Trailing 12 Months

-77.0%

How does AFIB drawdown profile look like?

AFIB Financial Health

Current Ratio

2.44

Debt/Equity

1.1

Debt/Cashflow

-1.82

AFIB Investor Care

Shares Dilution (1Y)

2.84%

Diluted EPS (TTM)

-2.81

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	16.9M	18.1M	19.7M	7.2M
2022	17.4M	16.7M	15.8M	16.4M
2021	10.5M	14.0M	15.5M	17.3M
2020	4.2M	5.7M	7.1M	8.5M
2019	0	0	0	2.8M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Acutus Medical, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 01, 2024	mukai takeo	sold (taxes)	-1,779	0.21	-8,475	cfo
Feb 06, 2024	sohn tom	sold (taxes)	-1,311	0.173	-7,582	svp, gen. counsel & secretary
Feb 01, 2024	sohn tom	sold (taxes)	-1,090	0.191	-5,709	svp, gen. counsel & secretary
Feb 01, 2024	mukai takeo	sold (taxes)	-547	0.191	-2,869	cfo
Jan 07, 2024	mathews kevin	sold (taxes)	-1,198	0.189	-6,342	svp, commercial
Jan 07, 2024	roman david	sold (taxes)	-4,552	0.189	-24,086	president & ceo
Sep 01, 2023	mukai takeo	sold (taxes)	-843	0.488	-1,729	cfo
Aug 05, 2023	sohn tom	sold (taxes)	-298	0.69	-433	svp, gen. counsel & secretary
Aug 05, 2023	mathews kevin	sold (taxes)	-92.46	0.69	-134	svp, commercial
Aug 02, 2023	mukai takeo	sold (taxes)	-	-	-501	cfo

Which funds bought or sold AFIB recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 16, 2024	VOISARD ASSET MANAGEMENT GROUP, INC.	unchanged	-	-121	1,636	-%
Apr 15, 2024	S.A. Mason LLC	unchanged	-	-89.00	1,203	-%
Apr 12, 2024	AdvisorNet Financial, Inc	unchanged	-	-78.00	1,058	-%
Mar 11, 2024	VANGUARD GROUP INC	reduced	-74.92	-736,855	57,761	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	new	-	4,600	4,600	-%
Feb 26, 2024	Virtu Financial LLC	added	184	-3,000	15,000	-%
Feb 14, 2024	CITADEL ADVISORS LLC	new	-	21,739	21,739	-%
Feb 14, 2024	Royal Bank of Canada	added	72.81	-	-	-%
Feb 14, 2024	DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	unchanged	-	-1,316,300	537,217	0.01%
Feb 14, 2024	ORBIMED ADVISORS LLC	unchanged	-	-1,310,160	534,709	0.01%

Are Funds Buying or Selling AFIB?

Are funds buying AFIB calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AFIB

No. of Funds

Unveiling Acutus Medical, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Nov 13, 2023	flynn james e	5.54%	5,731,096	SC 13D/A
Feb 13, 2023	capital world investors	2.8%	797,523	SC 13G/A
Jul 05, 2022	flynn james e	5.72%	5,731,096	SC 13D/A
Apr 27, 2022	flynn james e	5.74%	3,841,587	SC 13D/A
Feb 14, 2022	advent life sciences llp	5.8%	1,617,149	SC 13G/A
Feb 11, 2022	kerrisdale advisers, llc	0%	0	SC 13G/A
Feb 11, 2022	capital world investors	5.7%	1,600,000	SC 13G
Nov 18, 2021	orbimed advisors llc	9.5%	2,648,386	SC 13D/A
Aug 31, 2021	orbimed advisors llc	7.7%	6,881,953	SC 13D/A
Aug 26, 2021	flynn james e	5.81%	3,841,587	SC 13D/A

Recent SEC filings of Acutus Medical, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 04, 2024	144	Notice of Insider Sale Intent
Apr 01, 2024	8-K	Current Report
Apr 01, 2024	10-K	Annual Report
Mar 05, 2024	8-K	Current Report
Mar 04, 2024	4	Insider Trading
Feb 08, 2024	8-K	Current Report
Feb 07, 2024	4	Insider Trading
Feb 02, 2024	4	Insider Trading
Feb 02, 2024	4	Insider Trading
Jan 18, 2024	4	Insider Trading

Peers (Alternatives to Acutus Medical, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	186.2B	40.1B	-3.77%	-2.76%	32.53	4.64	-8.12%	-17.45%
BDX	67.7B	19.5B	-1.53%	-10.57%	53.87	3.47	4.02%	-22.04%
ALGN	22.5B	3.9B	-9.16%	-15.16%	50.45	5.81	3.42%	23.09%
BAX	20.0B	14.8B	-5.62%	-8.72%	7.55	1.35	2.12%	209.17%
MID-CAP
ATR	9.2B	3.5B	-0.49%	17.01%	32.33	2.64	4.97%	18.89%
HSIC	9.1B	12.3B	-5.22%	-14.61%	21.9	0.74	-2.44%	-22.68%
BIO	8.2B	2.7B	-16.90%	-39.13%	-12.81	3.06	-4.68%	82.43%
XRAY	6.3B	4.0B	-8.41%	-25.34%	-47.02	1.6	1.10%	85.84%
AXNX	3.4B	366.4M	-2.66%	12.41%	-562.64	9.32	33.86%	89.83%
PDCO	2.3B	6.6B	-4.93%	-3.92%	12.05	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.2B	3.2B	-14.38%	-20.49%	-1.83	0.39	7.73%	-1066.14%
ANIK	383.7M	166.7M	0.86%	-5.21%	-4.64	2.3	6.67%	-456.34%
ANGO	250.7M	324.0M	11.81%	-29.38%	-1.3	0.77	-3.19%	-337.41%
APYX	45.7M	52.3M	-28.65%	-55.25%	-2.44	0.87	17.61%	19.28%
AEMD	3.8M	3.7M	-10.98%	147.46%	-0.31	1.02	5.77%	8.23%

Acutus Medical, Inc. News

Latest updates

Acutus Medical, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2
Revenue	-100.0%	-	5,238,000	5,289,000	4,170,000	4,962,000	3,644,000	4,076,000	3,681,000	4,362,000	4,601,000	4,709,000	3,591,000	2,574,000	3,173,000	1,134,000	1,583,000	1,114,500	646,000	734,000
Gross Profit	267.2%	5,614,000	-3,357,000	-2,774,000	-2,620,000	10,278,000	-3,307,000	-5,621,000	-3,260,000	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-413.9%	-30,072,000	9,579,000	14,397,000	14,687,000	11,727,000	17,154,000	-20,549,000	35,370,000	34,262,000	31,690,000	32,009,000	31,424,000	30,580,000	29,435,000	20,599,000	19,183,000	-	31,810,000	14,609,000
S&GA Expenses	-264.4%	-12,214,500	7,432,000	9,284,000	9,565,000	9,447,000	9,679,000	14,143,000	14,385,000	15,865,000	15,805,000	15,601,000	16,252,000	15,164,000	15,833,000	9,125,000	10,235,000	-	7,978,000	6,927,000
R&D Expenses	-396.8%	-14,229,500	4,795,000	6,799,000	6,117,000	6,269,000	5,946,000	7,935,000	8,003,000	8,840,000	9,299,000	9,174,000	9,370,000	8,962,000	8,343,000	8,176,000	7,973,000	7,540,000	5,865,000	5,247,000
EBITDA Margin	26.2%	-0.84	-1.14	-1.62	-0.30	-1.73	-4.73	-4.92	-6.72	-6.15	-6.78	-7.72	-9.93	-11.07	-	-	-	-	-	-
Interest Expenses	9.6%	1,544,500	1,409,000	1,395,000	1,307,000	1,290,000	1,109,000	1,290,000	1,411,000	1,415,000	1,441,000	1,456,000	1,388,000	1,416,000	1,366,000	1,370,000	1,354,000	-	1,394,000	13,769,000
Income Taxes	-116.0%	-12,000	75,000	-	-	82,000	-	-	-	-	-	-	-	23,000	-	-	-	-	-	-
Earnings Before Taxes	373.2%	35,965,000	-13,162,000	-18,346,000	-16,315,000	15,190,000	-20,425,000	5,718,000	-40,017,000	-31,264,000	-28,511,000	-28,727,000	-29,181,000	-29,379,000	-31,288,000	-23,193,000	-18,098,000	-	-	-
EBT Margin	0.3%	-1.66	-1.66	-2.21	-0.94	-2.42	-5.46	-5.63	-7.41	-6.82	-7.48	-8.44	-10.79	-12.05	-	-	-	-	-	-
Net Income	-155.1%	-33,765,000	-13,237,000	-18,346,000	-16,315,000	15,108,000	-20,425,000	5,718,000	-40,017,000	-31,264,000	-28,511,000	-28,727,000	-29,181,000	-29,421,000	-31,288,000	-23,193,000	-18,098,000	-	-32,085,000	-30,345,000
Net Income Margin	-583.4%	-11.40	-1.67	-2.21	-0.94	-2.42	-5.46	-5.63	-7.41	-6.82	-7.49	-8.44	-10.80	-12.05	-	-	-	-	-	-
Free Cashflow	-16.8%	-16,838,000	-14,418,000	-15,352,000	-16,732,000	-14,457,000	-22,108,000	-23,730,000	-28,688,000	-25,986,000	-27,931,000	-25,763,000	-29,993,000	-27,534,000	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Assets	-36.3%	54.00	85.00	100	116	133	115	138	132	170	197	141	162	193	213	72.00	105
Current Assets	-36.3%	46.00	73.00	87.00	102	118	94.00	116	104	126	156	102	116	151	176	46.00	82.00
Cash Equivalents	8.7%	26.00	24.00	23.00	23.00	26.00	32.00	51.00	12.00	24.00	59.00	7.00	9.00	25.00	58.00	24.00	10.00
Inventory	-72.8%	4.00	16.00	16.00	15.00	13.00	15.00	15.00	18.00	16.00	15.00	15.00	14.00	13.00	11.00	12.00	8.00
Net PPE	-87.5%	1.00	7.00	7.00	8.00	9.00	10.00	11.00	13.00	14.00	15.00	15.00	15.00	12.00	10.00	8.00	4.00
Goodwill	-	-	-	-	-	-	-	-	-	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00
Liabilities	3.4%	55.00	53.00	57.00	56.00	58.00	57.00	62.00	63.00	64.00	64.00	65.00	62.00	66.00	60.00	75.00	78.00
Current Liabilities	28.3%	19.00	15.00	18.00	17.00	20.00	18.00	23.00	17.00	19.00	18.00	18.00	18.00	22.00	16.00	31.00	32.00
Long Term Debt	-100.0%	-	35.00	35.00	35.00	34.00	34.00	34.00	41.00	40.00	40.00	40.00	39.00	39.00	39.00	39.00	38.00
LT Debt, Non Current	-6.1%	33.00	35.00	35.00	35.00	34.00	34.00	34.00	41.00	40.00	40.00	40.00	39.00	39.00	39.00	39.00	38.00
Shareholder's Equity	-100.0%	-	32.00	44.00	60.00	75.00	58.00	77.00	69.00	106	134	76.00	100	127	153	-	-
Retained Earnings	-6.0%	-600	-566	-553	-534	-518	-533	-513	-518	-478	-447	-418	-390	-361	-331	-300	-259
Additional Paid-In Capital	0.2%	600	599	598	596	594	592	590	588	585	581	495	490	487	484	36.00	33.00
Shares Outstanding	0.1%	29.00	29.00	29.00	29.00	29.00	28.00	28.00	28.00	28.00	29.00	28.00	28.00	28.00	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																			(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2
Cashflow From Operations	-28.6%	-18,013	-14,008	-14,582	-16,515	-12,947	-21,353	-23,100	-27,600	-22,600	-27,185	-23,615	-26,300	-24,131	-26,277	-17,203	-17,558	-	-	-
Share Based Compensation	-247.4%	-1,883	1,278	1,734	1,904	1,894	1,884	2,581	3,032	3,491	3,577	3,776	2,910	2,831	6,374	1,157	1,741	-	812	803
Cashflow From Investing	-33.8%	11,220	16,949	15,137	15,249	12,217	3,365	73,169	15,999	-11,424	-3,532	21,850	12,172	-9,569	-106,905	20,933	31,717	-	-	-
Cashflow From Financing	74.4%	-495	-1,935	-21.00	-213	-15.00	-458	-11,601	-42.00	-514	82,232	229	-2,378	433	167,115	-531	-2,584	-	-	-
Buy Backs	-2391.7%	-275	12.00	46.00	217	49.00	17.00	45.00	-	-	-	-	-	-	-	-	-	-	-	-

AFIB Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Statement of Comprehensive Income [Abstract]
Revenue	$ 7,164	$ 3,031
Cost of products sold	10,301	4,941
Gross loss	(3,137)	(1,910)
Operating expenses (income):
Research and development	3,482	3,118
Selling, general and administrative	14,066	20,315
Goodwill impairment	0	12,026
Change in fair value of contingent consideration	123	1,053
Gain on sale of business	(9,080)	(79,465)
Total operating expenses (income)	8,591	(42,953)
(Loss) income from operations	(11,728)	41,043
Other income (expense):
Loss on debt extinguishment	0	(7,947)
Change in fair value of warrant liability	2,937	33
Interest income	2,588	868
Interest expense	(5,655)	(5,149)
Total other expense, net	(130)	(12,195)
(Loss) income from continuing operations before income taxes	(11,858)	28,848
Income tax expense	63	15
Net (loss) income from continuing operations	(11,921)	28,833
Discontinued operations:
Loss from discontinued operations before income taxes	(69,530)	(68,382)
Income tax expense - discontinued operations	212	67
Loss from discontinued operations	(69,742)	(68,449)
Net loss	(81,663)	(39,616)
Other comprehensive income (loss):
Unrealized gain on marketable securities	7	39
Foreign currency translation adjustment	(4)	(691)
Comprehensive loss	$ (81,660)	$ (40,268)
Net (loss) earnings per share, basic:
Income (loss) from continuing operations, basic (in dollars per share)	$ (0.41)	$ 1.02
Loss from discontinued operations , basic (in dollars per share)	(2.40)	(2.42)
Net loss per common share, basic (in dollars per share)	(2.81)	(1.40)
Net earnings (loss) per share, diluted:
Income (loss) from continuing operations , diluted (in dollars per share)	(0.41)	0.78
Loss from discontinued operations, diluted (in dollars per share)	(2.40)	(2.42)
Net Loss per common share, diluted (in dollars per share)	$ (2.81)	$ (1.40)
Weighted Average Number of Shares Outstanding [Abstract]
Weighted average number of common shares outstanding, basic (in shares)	29,095,294	28,471,389
Weighted average number of common shares outstanding, diluted- continuing operations (in shares)	29,095,294	37,152,367
Weighted average number of common shares outstanding, diluted- discontinued operations and net loss per common share (in shares)	29,095,294	28,471,389

AFIB Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 19,170	$ 25,584
Marketable securities, short-term	3,233	44,863
Restricted cash, short-term	7,030	5,764
Accounts receivable	11,353	17,919
Inventory	4,278	1,794
Employer retention credit receivable	0	4,703
Prepaid expenses and other current assets	678	1,254
Current assets of discontinued operations (Note 3)	510	15,986
Total current assets	46,252	117,867
Noncurrent assets
Property and equipment, net	825	1,669
Right-of-use assets, net	3,189	3,872
Other assets	94	94
Non-current assets of discontinued operations (Note 3)	3,600	9,938
Total assets	53,960	133,440
Current liabilities:
Accounts payable	2,761	2,473
Accrued liabilities	2,887	3,310
Contingent consideration, short-term	0	1,800
Operating lease liabilities, short-term	718	319
Long-term debt, current portion	1,864	0
Warrant liability	409	3,346
Current liabilities of discontinued operations (Note 3)	10,303	8,624
Total current liabilities	18,942	19,872
Operating lease liabilities, long-term	3,243	4,103
Long-term debt	32,654	34,434
Other long-term liabilities	0	12
Total liabilities	54,839	58,421
Commitments and contingencies (Note 12)
Stockholders' (deficit) equity
Preferred stock, $0.001 par value; 5,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 6,666 shares of the preferred stock, designated as Series A Common Equivalent Preferred Stock, are issued and outstanding as of December 31, 2023 and December 31, 2022, respectively	0	0
Common stock, $0.001 par value; 260,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 29,313,667 and 28,554,656 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively	29	29
Additional paid-in capital	599,935	594,173
Accumulated deficit	(599,977)	(518,314)
Accumulated other comprehensive loss	(866)	(869)
Total stockholders' equity	(879)	75,019
Total liabilities and stockholders' equity	$ 53,960	$ 133,440

About Acutus Medical, Inc.

Acutus Medical, Inc., an arrhythmia management company, designs, manufactures, and markets various tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. Its product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact force ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. The company was incorporated in 2011 and is headquartered in Carlsbad, California.

CEO	Mr. David Harrison Roman
WEBSITE	acutusmedical.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	225

Acutus Medical, Inc. Frequently Asked Questions

What is the ticker symbol for Acutus Medical, Inc.? What does AFIB stand for in stocks?

AFIB is the stock ticker symbol of Acutus Medical, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Acutus Medical, Inc. (AFIB)?

As of Fri Apr 19 2024, market cap of Acutus Medical, Inc. is 5.05 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AFIB stock?

You can check AFIB's fair value in chart for subscribers.

What is the fair value of AFIB stock?

You can check AFIB's fair value in chart for subscribers. The fair value of Acutus Medical, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Acutus Medical, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AFIB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Acutus Medical, Inc. a good stock to buy?

The fair value guage provides a quick view whether AFIB is over valued or under valued. Whether Acutus Medical, Inc. is cheap or expensive depends on the assumptions which impact Acutus Medical, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AFIB.

What is Acutus Medical, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, AFIB's PE ratio (Price to Earnings) is -0.06 and Price to Sales (PS) ratio is 0.71. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AFIB PE ratio will change depending on the future growth rate expectations of investors.